These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17692108)

  • 41. Increased plasma concentrations of N-terminal pro-B-type natriuretic peptide in patients with mild primary hyperparathyroidism.
    Almqvist EG; Becker C; Bondeson AG; Bondeson L; Svensson J; Svensson SE
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):760-6. PubMed ID: 17121527
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
    Zhigang Z; Wenlu S
    Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R; Pahalajani G; Agarwal A; Zippe C
    Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preliminary study with bicalutamide in heterosexual and homosexual patients with prostate cancer: a possible implication of androgens in male homosexual arousal.
    Motofei IG; Rowland DL; Popa F; Kreienkamp D; Paunica S
    BJU Int; 2011 Jul; 108(1):110-5. PubMed ID: 20955264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
    Penson DF; Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M
    J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma N-terminal pro-B-type natriuretic peptide as long-term prognostic marker after major vascular surgery.
    Feringa HH; Schouten O; Dunkelgrun M; Bax JJ; Boersma E; Elhendy A; de Jonge R; Karagiannis SE; Vidakovic R; Poldermans D
    Heart; 2007 Feb; 93(2):226-31. PubMed ID: 16914484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
    Iversen P; Roder MA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.
    Dockery F; Bulpitt CJ; Agarwal S; Donaldson M; Rajkumar C
    Clin Sci (Lond); 2003 Feb; 104(2):195-201. PubMed ID: 12546642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between changes in N-terminal pro-brain natriuretic peptide levels and changes in left ventricular mass index in stable hemodialysis patients.
    Choi SY; Lee JE; Jang EH; Kim MO; Baek H; Ki CS; Park SW; Kim DJ; Huh WS; Oh HY; Kim YG
    Nephron Clin Pract; 2008; 110(2):c93-100. PubMed ID: 18815449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
    Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
    Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression.
    Augustin H; Freibauer C; Bayer L; Lunglmayr G; Tschurlovich F; Kuber W; Pummer K
    Prostate Cancer Prostatic Dis; 2006; 9(3):279-83. PubMed ID: 16702984
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
    Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
    Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
    J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results.
    Prapotnich D; Cathelineau X; Rozet F; Barret E; Mombet A; Cathala N; Sanchez-Salas RE; Vallancien G
    World J Urol; 2009 Oct; 27(5):627-35. PubMed ID: 19247669
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of thrombotic thrombocytopenic purpura in metastatic prostate cancer with only endocrine therapy.
    Kanesvaran R; Phipps C; Cheng CW; Chan MM; Khoo D; Tan MH
    Ann Acad Med Singap; 2010 Jul; 39(7):580-2. PubMed ID: 20697679
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of Testosterone on Natriuretic Peptide Levels.
    Bachmann KN; Huang S; Lee H; Dichtel LE; Gupta DK; Burnett JC; Miller KK; Wang TJ; Finkelstein JS
    J Am Coll Cardiol; 2019 Mar; 73(11):1288-1296. PubMed ID: 30898204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.